Skip to content
Sinha P, Linas BP. Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality. Clin Infect Dis. 2021 May 6:ciab409. doi: 10.1093/cid/ciab409. Epub ahead of print. PMID: 33956936.

Recent randomized trials suggest that interleukin-6 inhibitors like tocilizumab have mortality benefit for patients with severe coronavirus disease-2019. We employed a decision tree to investigate their cost-effectiveness and found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16520 per quality-adjusted life year gained (95% credible interval 10760-51530).

assignment_turned_in Registrations
   
Please login to view this page.
Please login to view this page.
Please login to view this page.
No item in the cart
Go shopping!